BiotechTube

Triptorelin

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Normal Oocyte Donors

Conditions

Normal Oocyte Donors

Trial Timeline

Aug 1, 2014 → Mar 1, 2015

NCT ID
NCT02208986

About Triptorelin

Triptorelin is a pre-clinical stage product being developed by Merck for Normal Oocyte Donors. The current trial status is completed. This product is registered under clinical trial identifier NCT02208986. Target conditions include Normal Oocyte Donors.

What happened to similar drugs?

4 of 6 similar drugs in Normal Oocyte Donors were approved

Approved (4) Terminated (2) Active (2)
✅DonepezilEisaiApproved
✅Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
✅cyclosporine micro-emulsionNovartisApproved
✅Aspirin 100 mg + PlaceboBayerApproved
🔄Gadopentetate dimeglumine (Magnevist)BayerPhase 3
🔄lixivaptan + placeboBiogenPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02208986Pre-clinicalCompleted

Competing Products

20 competing products in Normal Oocyte Donors

See all competitors
ProductCompanyStageHype Score
RoxadustatAstellas PharmaPhase 1
29
DonepezilEisaiApproved
43
eribulin mesylateEisaiPhase 2
35
Lurasidone HClSumitomo PharmaPhase 1
29
Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
39
Temozolomide + VorinostatMerckPhase 2
35
LDE225NovartisPhase 1
29
LDK378NovartisPhase 1
29
cyclosporine micro-emulsionNovartisApproved
35
LDK378NovartisPhase 1
29
LEE011NovartisPhase 1
29
LEE011NovartisPhase 1
29
mycophenolate mofetilRochePhase 1
29
filgrastimAmgenPre-clinical
26
PF-06423264PfizerPhase 1
21
PF-05221304PfizerPhase 1
29
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose SolutionBristol Myers SquibbPhase 1
29
tolebrutinibSanofiPhase 1
29
Venglustat (GZ402671)SanofiPhase 1
29
RilzabrutinibSanofiPhase 1
29